HUE027534T2 - Notch pathway inhibitory compound - Google Patents

Notch pathway inhibitory compound Download PDF

Info

Publication number
HUE027534T2
HUE027534T2 HUE12741192A HUE12741192A HUE027534T2 HU E027534 T2 HUE027534 T2 HU E027534T2 HU E12741192 A HUE12741192 A HU E12741192A HU E12741192 A HUE12741192 A HU E12741192A HU E027534 T2 HUE027534 T2 HU E027534T2
Authority
HU
Hungary
Prior art keywords
cancer
compound
mmol
pharmaceutically acceptable
add
Prior art date
Application number
HUE12741192A
Other languages
English (en)
Hungarian (hu)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE027534T2 publication Critical patent/HUE027534T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
HUE12741192A 2011-07-27 2012-07-18 Notch pathway inhibitory compound HUE027534T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
HUE027534T2 true HUE027534T2 (en) 2016-11-28

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12741192A HUE027534T2 (en) 2011-07-27 2012-07-18 Notch pathway inhibitory compound

Country Status (36)

Country Link
US (1) US8569286B2 (enExample)
EP (1) EP2736920B1 (enExample)
JP (1) JP6027110B2 (enExample)
KR (1) KR101578309B1 (enExample)
CN (1) CN103732612B (enExample)
AP (1) AP4080A (enExample)
AR (1) AR087107A1 (enExample)
AU (1) AU2012287251B2 (enExample)
BR (1) BR112014001600B1 (enExample)
CA (1) CA2841178C (enExample)
CL (1) CL2014000175A1 (enExample)
CO (1) CO6862159A2 (enExample)
CR (1) CR20140036A (enExample)
CY (1) CY1116645T1 (enExample)
DK (1) DK2736920T3 (enExample)
DO (1) DOP2014000011A (enExample)
EA (1) EA023044B1 (enExample)
EC (1) ECSP14013179A (enExample)
ES (1) ES2544937T3 (enExample)
GT (1) GT201400012A (enExample)
HR (1) HRP20150771T1 (enExample)
HU (1) HUE027534T2 (enExample)
IL (1) IL229988A (enExample)
JO (1) JO3148B1 (enExample)
MA (1) MA35611B1 (enExample)
ME (1) ME02171B (enExample)
MX (1) MX356536B (enExample)
MY (1) MY184303A (enExample)
PE (1) PE20141061A1 (enExample)
PH (1) PH12014500215B1 (enExample)
PL (1) PL2736920T3 (enExample)
PT (1) PT2736920E (enExample)
RS (1) RS54135B1 (enExample)
SI (1) SI2736920T1 (enExample)
TW (1) TWI568730B (enExample)
WO (1) WO2013016081A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
ES2881801T3 (es) * 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
RU2754452C2 (ru) * 2016-04-12 2021-09-02 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
KR102463617B1 (ko) 2016-05-20 2022-11-03 일라이 릴리 앤드 캄파니 Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법
SG10202107832UA (en) 2016-08-31 2021-09-29 Lilly Co Eli Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
JP7522661B2 (ja) * 2018-05-06 2024-07-25 アヤラ ファーマシューティカルズ インコーポレイテッド ビスフルオロアルキル-1,4-ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
TW202034900A (zh) 2018-10-02 2020-10-01 美商頻率醫療公司 有關耳用治療劑之醫藥組成物及方法
WO2020210388A1 (en) 2019-04-08 2020-10-15 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
MX2024008648A (es) 2022-01-12 2024-09-23 Denali Therapeutics Inc Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2272305A1 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds as .beta.-amyloid peptide release inhibitors
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO1999067219A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP4662914B2 (ja) 2003-02-04 2011-03-30 エフ.ホフマン−ラ ロシュ アーゲー ガンマ−セクレターゼ阻害剤としてのマロンアミド誘導体
SI1711470T1 (sl) 2003-09-09 2009-08-31 Hoffmann La Roche Derivati malonamida, ki blokirajo aktivnost gama-sekretaze
PL1673347T3 (pl) 2003-10-06 2016-01-29 Hoffmann La Roche Podstawione pochodne dibenzo-azepiny i benzo-diazepiny użyteczne jako inhibitory gamma-sekretazy
CA2645756C (en) 2006-03-27 2013-12-31 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma secretase inhibitors
WO2008092786A1 (en) * 2007-02-02 2008-08-07 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
CN101909633B (zh) 2008-01-11 2012-05-30 霍夫曼-拉罗奇有限公司 γ-分泌酶抑制剂用于治疗癌症的应用
US8637493B2 (en) * 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
AR087107A1 (es) 2014-02-12
BR112014001600A2 (pt) 2017-02-21
RS54135B1 (sr) 2015-12-31
HRP20150771T1 (hr) 2015-08-28
ME02171B (me) 2015-10-20
ES2544937T3 (es) 2015-09-07
MA35611B1 (fr) 2014-11-01
SI2736920T1 (sl) 2015-08-31
MX356536B (es) 2018-06-01
KR101578309B1 (ko) 2015-12-16
HK1194086A1 (en) 2014-10-10
AP4080A (en) 2017-03-29
WO2013016081A1 (en) 2013-01-31
PE20141061A1 (es) 2014-09-06
MX2014001084A (es) 2014-02-27
JO3148B1 (ar) 2017-09-20
GT201400012A (es) 2014-07-16
ECSP14013179A (es) 2014-03-31
KR20140026624A (ko) 2014-03-05
US20130029972A1 (en) 2013-01-31
PH12014500215B1 (en) 2018-09-07
CR20140036A (es) 2014-03-21
PT2736920E (pt) 2015-09-16
AP2014007362A0 (en) 2014-01-31
EA201490161A1 (ru) 2014-04-30
CY1116645T1 (el) 2017-03-15
JP6027110B2 (ja) 2016-11-16
DK2736920T3 (en) 2015-07-20
MY184303A (en) 2021-03-31
CL2014000175A1 (es) 2014-08-22
CA2841178C (en) 2016-12-20
AU2012287251B2 (en) 2015-05-14
CN103732612B (zh) 2015-09-23
CN103732612A (zh) 2014-04-16
EP2736920B1 (en) 2015-07-01
CO6862159A2 (es) 2014-02-10
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
NZ618891A (en) 2015-12-24
PL2736920T3 (pl) 2015-11-30
DOP2014000011A (es) 2014-07-31
IL229988A (en) 2017-07-31
TW201315732A (zh) 2013-04-16
TWI568730B (zh) 2017-02-01
EP2736920A1 (en) 2014-06-04
AU2012287251A1 (en) 2014-01-30
BR112014001600B1 (pt) 2022-09-13
US8569286B2 (en) 2013-10-29
JP2014527042A (ja) 2014-10-09
PH12014500215A1 (en) 2014-03-17

Similar Documents

Publication Publication Date Title
DK2736920T3 (en) CONNECTION TO INHIBITION OF NOTCH SIGNAL ROAD
EP3283079B1 (en) Targeted treatment of leiomyosarcoma
MX2015002887A (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
KR20210135521A (ko) 피롤로피라졸 유도체
TW201124398A (en) Quinazoline derivatives
CN118684666A (zh) Kif18a抑制剂及其用途
EP4010343B1 (en) 7,8-dihydro-4h-pyrazolo[4,3-c]azepine-6-one compounds
CN114555597B (zh) 异柠檬酸脱氢酶(idh)抑制剂
HK1194086B (en) Notch pathway signaling inhibitor compound
NZ618891B2 (en) Notch pathway signaling inhibitor compound
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用
HK1251166B (en) Targeted treatment of leiomyosarcoma